Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
SHSE:600436's PEG Ratio is ranked worse than 86.86% of 350
companies
in the Drug Manufacturers industry
Industry Median: 1.8
vs SHSE:600436: 8.08
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Zhangzhou Pientzehuang Pharmaceutical Co PEG Ratio Related Terms
Zhangzhou Pientzehuang Pharmaceutical Co PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhangzhou Pientzehuang Pharmaceutical Co PEG Ratio Chart
Zhangzhou Pientzehuang Pharmaceutical Co Annual Data
SHSE:600436 vs LLY, JNJ, ABBV: PEG Ratio Comparison
For the Drug Manufacturers - General subindustry, Zhangzhou Pientzehuang Pharmaceutical Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhangzhou Pientzehuang Pharmaceutical Co PEG Ratio vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) has a PEG Ratio of 8.08 as of Jul. 19, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Zhangzhou Pientzehuang Pharmaceutical Co and its competitors. This is 188% above median its historical median of 2.81. Over the past decade, Zhangzhou Pientzehuang Pharmaceutical Co's PEG Ratio has ranged from 1.61 to 15.61. According to the industry distribution chart, Zhangzhou Pientzehuang Pharmaceutical Co ranks #304 out of 350 companies in the Drug Manufacturers industry, placing it in the top 86.9%.
Is Zhangzhou Pientzehuang Pharmaceutical Co's PEG Ratio too high?
Zhangzhou Pientzehuang Pharmaceutical Co's current PEG Ratio of 8.08 is 188% above median its 10-year median of 2.81. Over the past 10 years, this metric has ranged from a low of 1.61 to a high of 15.61. The Drug Manufacturers industry median PEG Ratio is 1.80. Zhangzhou Pientzehuang Pharmaceutical Co's value of 8.08 is 348.9% above this industry median. Based on the distribution chart, Zhangzhou Pientzehuang Pharmaceutical Co ranks #304 out of 350 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zhangzhou Pientzehuang Pharmaceutical Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhangzhou Pientzehuang Pharmaceutical Co's PEG Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Zhangzhou Pientzehuang Pharmaceutical Co ranks #304 out of 350 companies for PEG Ratio. This places Zhangzhou Pientzehuang Pharmaceutical Co in the lower half of its industry. The industry median PEG Ratio is 1.80. Zhangzhou Pientzehuang Pharmaceutical Co's value of 8.08 is 348.9% above this benchmark. Historically, Zhangzhou Pientzehuang Pharmaceutical Co's own PEG Ratio has ranged from 1.61 to 15.61 over the past decade. While the company's 10-year median is 2.81 vs. the industry median of 1.80, Zhangzhou Pientzehuang Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.80, based on 350 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhangzhou Pientzehuang Pharmaceutical Co's current PEG Ratio of 8.08 is 348.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Zhangzhou Pientzehuang Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhangzhou Pientzehuang Pharmaceutical Co's current PEG Ratio is 8.08, which is 188% above median its own 10-year median of 2.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhangzhou Pientzehuang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥172.67, compared to a current price of ¥146.63 — trading 15.1% below its estimated fair value. The current PEG Ratio is 8.08, which is 188% above median its 10-year median of 2.81 and 348.9% above the Drug Manufacturers industry median of 1.80. Zhangzhou Pientzehuang Pharmaceutical Co's overall GF Score™ is 86/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436), the current PEG Ratio is 8.08 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) Overvalued in 2026?
Based on GuruFocus' analysis, Zhangzhou Pientzehuang Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥146.63 is trading 15.1% below its estimated GF Value™ of ¥172.67.
GuruFocus considers Zhangzhou Pientzehuang Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600436:
PEG Ratio: 8.08 (188% above median its 10-year median of 2.81)
GF Value™: ¥172.67 vs. price of ¥146.63 (15.1% below fair value)
Industry Position: 348.9% above the Drug Manufacturers median (#304 of 350)
No single metric tells the full story. See the SHSE:600436 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhangzhou Pientzehuang Pharmaceutical Co Business Description
Zhangzhou Pientzehuang Pharmaceutical Co Ltd produces and sells Chinese medicines. The company's product categories include tablets, hard capsules, granules, pills (water pills, honey pills), syrups, tinctures (including external use), ointments, lozenges, decoctions, Chinese herbal medicine slices (including direct oral slices) (clean preparation); production of candy products (candy), health food products; and production of beverages (solid beverages).
86GF Score
Get the complete analysis for SHSE:600436
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600436 has been successfully added to your 
